<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNRjQxejdsT3kxbElDTURJaDhMNURDUVEwY25UZERiY0FKTzNSRmFpSXJyVXdUemk1angza1Ric3YzTFcwN0JBdVBjYVlLTmVWems3YkZXRm5xN0NVdngzcXVOUFdrS1VpZk5TN1E3cHdDQndOSFo2RVNsS3h
Why DME Stock advanced +0.45% Today — RQD Quant Desk Flash
DME Corp. (DME) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is DME stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-22, DME Corp. (NASDAQ: DME) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $48.50 (+0.45% 1D, market cap $3.15B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 0 tracked US Equity issuers, DME ranks #1 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does DME compare to PRVA and ABM in the US Equity sector?
▼
Within the US Equity sector (Public Equity), DME carries a Roarable C (62/100 RQD), trailing P/E of 21.4x, gross margin of —, and ROIC of —. By comparison, PRVA (Privia Health Group Inc.) holds a C grade (63/100 RQD, P/E 122.6x, ROIC 10.5%, cap $3.15B) and ABM (ABM Industries Incorporated) posts a C- grade (61/100 RQD, P/E 19.5x, ROIC 7.6%, cap $3.15B). Among the 5-stock peer group, SLDE leads on earnings multiple (7.2x) while SLDE leads on capital efficiency (39.9% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for DME?
▼
For DME Corp. (DME), key quantitative strengths include Established market leader in US Equity with deep daily trading liquidity and sector rank #1 in US Equity, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 15.1%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where to Enter $DME, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL Trailing 12 Months: 2.2% FCF Margin ($88.3M FCF) & 52% Gross Margin
20D Institutional Volume Accumulation (±4.3% realized swing band)
Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment
⚔️ Adversarial Opposing Case: Why the DME Bull Thesis Could Fail
Even with a 62/100 (C) score, DME faces multiple-compression risk if 21.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($46.56) or 200D SMA ($44.13) invalidates the momentum regime and cuts Target Base ($49.37) toward Bear Floor ($38.51).
Why DME Stock advanced +0.45% Today — RQD Quant Desk Flash
DME Corp. (DME) advanced +0.45% to $48.50, trading at 52% of its 52-week range ($35.89 – $60.14). Solid steady margins (steady margins), mixed timing at 21x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 52% of its 52-week range ($35.89 – $60.14) with RSI-14 at 54 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.3% around $48.50 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $88.3M annual free cash flow.
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUk9OSGJvMXk0TTN2am5SOHlzWE5wcURIeWc4WFpfOXR0OTQtZllYWlpidjlBckdIQkRPQ1ZEOXMtZ3BNaDJHaDRXd0E5Q0hpdFBIUUFrTEpVd3ZxV0JFTG10aDA2eVgxNW00bVFxNWVZbkhTRHplNzdCUk5
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPR3kwREllcEFsUm1qR1ZDenFMX0wwb1JWdmVEVW1DNFloYVVMNUF3NkFQZTVfNEdyd0s2aUxja09JbnllLXItcGZJaTYyYThkbC1SWUhEM1paNDc2Q0hnUUFyd3pJWG5VMWRCanEtRGtQQWlZQlRiMEJrRHR
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQeGNDSW9SbTA2cG9ia1pqY29yOTV2U3hRbHdDMnFhNTJkUUZNY3NHRDdBOGJySDMza0I1YUtvNm84WEZkdm8xcDd6SWpTQXhfQmY4Q1RnQnZTWHFPQ0JVX3M4c1hZbzVHck5JVHg3Mm5jT3R4OFU2VkNocEp
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9sWUk4eThPZ1NBUk9TVzdVZjZjMlhvUDFKSVZYWXRSMmViU2lNcGlqYW1SZGg3SWJVVnlaNkRrQkFvWXc4MEhfMFdRWE52LVZJSk8tUXRnSVA2c0tHdjJZZUZxOWxLeU52SjhSc2xub3lxN1NPOFNLTTJB?oc
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOd2pJTWxPWmZiV1llaG1GS095NUJPTGk2eXAxOHVXX2VydFlpZUZDSFVCLTlscklOVE84dXZmdm1fa19XZzNYTDloSjhQS05yOVI4c2JYWWZBWDVhWHlIWTViWjJIOWhTemJVZGpORmctLXBiX0FKVUJDbkt
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBCN2RCZDE5enkybnNNWlB3XzFrZjU5RlJfZHBQVjlRRzBPcU1rRXFTdUNta290RHd6WVktZXF2bVpKNHhwemx5amFXWGFlRmJEcHNtNzNpckZhRXJxU3QzanVGenNqaEdndGVISl9aOC10Q1B1UnJJ?oc=5"
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPRkJYSXB1dkpMYU4zNE1kc3RzX3JtSUpTampwaWdzRFB1QXVWbDl1Qm5KZWRMeXhZdDZzX1l5b2V3RjQxblhGWUhKUXlnay1kVGZncFZKa29IODlWb2lhZnJsYTNxMW9uUFJTc0lBRlBSY3M5UGRnQlZ5eWc
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNcTlOMzIwRFNMU3hxbU9YWTBxem1uMjZOLS02Rzh0UURsWmQ3bmNyZ1F3MENFSnZIRmdYQ1ZIUldlY2pvWTMwTXQwdXgtTkxuVVJpSlFlVGNUZFRSY2JKakJlMWRubmlTamcxMTl1cmlkVjBSbjVMbm16Znk
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOZmpwSUpveFFUVjM0UW4teG4wbE40RWpURW5FRmZEWDN3UlZiSHdmclNhaDVkaWRLMkQ0UGlDR21xakd3elNJR2hjUGZHZTVXN1VxSUpKOHpjQVh4RXZaNjZybldkMUVKTHhyeno1V3lHbTVZZGxlTHRZT1V
Scheduled RQD Strong Buys & Whale Accumulation Briefing (DME Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
DME Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs
Test Your Own DME Growth & WACC Assumptions
DME passes the 8-variable Beneish M-Score audit (< -1.78), confirming GAAP earnings are backed by real operating cash flow.
DME clears the 2.99 Altman Z-Score threshold with negligible 24-month credit distress risk.
DME generates a positive 7.7% spread over WACC (7.5%), indicating competitive stability.
DME reduced diluted share count YoY, increasing each shareholder’s ownership slice of free cash flow.
DME Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DME today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DME. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DME)
1. Head-to-Head US Equity Peer Comparison (DME vs. PRVA, ABM, PRIM, SLDE)
Industry: Public Equity (0 Tracked Issuers)Across 0 tracked US Equity securities in the Roarable RQD universe, DME Corp. (DME) ranks #1 by composite RQD confidence (62/100, grade C) and #1 by equity capitalization ($3.15B). Within this direct 5-issuer industry benchmark cohort, SLDE leads on earnings valuation at 7.2x trailing P/E, while SLDE leads on capital efficiency and profitability with 39.9% ROIC and — gross margin. SLDE currently holds the highest overall quantitative score in the immediate peer group at 82/100 (A-) compared with DME at 62/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DME
ACTIVE
DME Corp. | C | 62/100 | 21.4x | — | — | +0.45% | $3.15B | Benchmark Subject |
| PRVA Privia Health Group Inc. | C | 63/100 | 122.6x | — | 10.5% | +0.37% | $3.15B | /prva-vs-dme → |
| ABM ABM Industries Incorporated | C- | 61/100 | 19.5x | 12.3% | 7.6% | -1.61% | $3.15B | /abm-vs-dme → |
| PRIM Primoris Services Corporation | C | 65/100 | 14.8x | 10.7% | 20.9% | -6.44% | $3.16B | /prim-vs-dme → |
| SLDE Slide Insurance Holdings Inc. | A- | 82/100 | 7.2x | — | 39.9% | +0.34% | $3.15B | /slde-vs-dme → |
2. DME Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTDME Corp. (DME) operates in Public Equity (US Equity) with an equity capitalization of $3.15B, trailing P/E of 21.4x, forward P/E of 18.2x, and EV/EBITDA of 14.6x. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. DME Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DME stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-22, DME Corp. (NASDAQ: DME) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $48.50 (+0.45% 1D, market cap $3.15B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 0 tracked US Equity issuers, DME ranks #1 in composite RQD confidence.
How does DME compare to PRVA and ABM in the US Equity sector?
Within the US Equity sector (Public Equity), DME carries a Roarable C (62/100 RQD), trailing P/E of 21.4x, gross margin of —, and ROIC of —. By comparison, PRVA (Privia Health Group Inc.) holds a C grade (63/100 RQD, P/E 122.6x, ROIC 10.5%, cap $3.15B) and ABM (ABM Industries Incorporated) posts a C- grade (61/100 RQD, P/E 19.5x, ROIC 7.6%, cap $3.15B). Among the 5-stock peer group, SLDE leads on earnings multiple (7.2x) while SLDE leads on capital efficiency (39.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DME?
For DME Corp. (DME), key quantitative strengths include Established market leader in US Equity with deep daily trading liquidity and sector rank #1 in US Equity, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 15.1%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DME trading relative to its 50-day, 200-day, and 52-week technical levels?
DME last traded at $48.50 (+0.45% on volume of 720,000 shares), positioning the stock +3.09% above its 50-day simple moving average ($47.05) and +8.70% above its 200-day simple moving average ($44.62). Across its 52-week range of $35.89 to $60.14, DME sits at the 52.0% percentile with a 14-day RSI of 54.0 (NEUTRAL RANGE) and an implied next-earnings move of ±4.3% ($46.41 to $50.59).
DME — DME Corp.: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
DME Corp. (DME) earns a live Roarable RQD composite score of 62/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $48.50 (+0.45% 1D, market capitalization $3.15B).
- Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (14/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (12/20) + Forensic Balance Sheet (14/20): Incorporates a 1.12x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of 0.58x.
2. Business Model, Unit Margins & SEC Financial Trajectory
DME Corp. (DME) operates in the Public Equity industry (US Equity sector) with an equity capitalization of $3.15B, gross margin of —, operating margin of —, and return on invested capital (ROIC) of —.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (C • RQD 62/100): Established market leader in US Equity with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 14/20. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $35.89 – $60.14 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 21.4x trailing P/E and 14.6x EV/EBITDA against — operating margins and a 1.12x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Public Equity (US Equity), DME carries a macro regime beta of 1.12 and gross margin of —.
- Key Question #1: Can DME sustain or expand its — operating margin and — ROIC against Public Equity peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $60.14 52-week high?
- Key Question #3: How sensitive is DME's 18.2x forward P/E multiple to US Equity capital spending cycles and macro interest-rate shifts (Beta 1.12x)?
DME Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for DME Corp. (DME) • Click "Debate This Headline" to argue it in the Roar Pit below
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNRjQxejdsT3kxbElDTURJaDhMNURDUVEwY25UZERiY0FKTzNSRmFpSXJyVXdUemk1angza1Ric3YzTFcwN0JBdVBjYVlLTmVWems3YkZXRm5xN0NVdngzcXVOUFdrS1VpZk5TN1E3cHdDQndOSFo2RVNsS3h
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUk9OSGJvMXk0TTN2am5SOHlzWE5wcURIeWc4WFpfOXR0OTQtZllYWlpidjlBckdIQkRPQ1ZEOXMtZ3BNaDJHaDRXd0E5Q0hpdFBIUUFrTEpVd3ZxV0JFTG10aDA2eVgxNW00bVFxNWVZbkhTRHplNzdCUk5
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPR3kwREllcEFsUm1qR1ZDenFMX0wwb1JWdmVEVW1DNFloYVVMNUF3NkFQZTVfNEdyd0s2aUxja09JbnllLXItcGZJaTYyYThkbC1SWUhEM1paNDc2Q0hnUUFyd3pJWG5VMWRCanEtRGtQQWlZQlRiMEJrRHR
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQeGNDSW9SbTA2cG9ia1pqY29yOTV2U3hRbHdDMnFhNTJkUUZNY3NHRDdBOGJySDMza0I1YUtvNm84WEZkdm8xcDd6SWpTQXhfQmY4Q1RnQnZTWHFPQ0JVX3M4c1hZbzVHck5JVHg3Mm5jT3R4OFU2VkNocEp
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9sWUk4eThPZ1NBUk9TVzdVZjZjMlhvUDFKSVZYWXRSMmViU2lNcGlqYW1SZGg3SWJVVnlaNkRrQkFvWXc4MEhfMFdRWE52LVZJSk8tUXRnSVA2c0tHdjJZZUZxOWxLeU52SjhSc2xub3lxN1NPOFNLTTJB?oc
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOd2pJTWxPWmZiV1llaG1GS095NUJPTGk2eXAxOHVXX2VydFlpZUZDSFVCLTlscklOVE84dXZmdm1fa19XZzNYTDloSjhQS05yOVI4c2JYWWZBWDVhWHlIWTViWjJIOWhTemJVZGpORmctLXBiX0FKVUJDbkt
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBCN2RCZDE5enkybnNNWlB3XzFrZjU5RlJfZHBQVjlRRzBPcU1rRXFTdUNta290RHd6WVktZXF2bVpKNHhwemx5amFXWGFlRmJEcHNtNzNpckZhRXJxU3QzanVGenNqaEdndGVISl9aOC10Q1B1UnJJ?oc=5"
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPRkJYSXB1dkpMYU4zNE1kc3RzX3JtSUpTampwaWdzRFB1QXVWbDl1Qm5KZWRMeXhZdDZzX1l5b2V3RjQxblhGWUhKUXlnay1kVGZncFZKa29IODlWb2lhZnJsYTNxMW9uUFJTc0lBRlBSY3M5UGRnQlZ5eWc
DME Bull vs. Bear Conversation Board — What's Your Call at $48.50?
3 Stocks on Our Radar Today — Entry, Hard Stop & Why
DME Stock & RQD Cockpit — Related SEC 10-K, Valuation Formula & Insider Research Hubs
Contextual Institutional Research Paths: Audit the step-by-step DME 2-Stage DCF Intrinsic Value Calculator , verify balance-sheet solvency via the DME Altman Z-Score 5-Ratio Test and DME Piotroski 9-Point F-Score , or screen the broader equity universe using the Best Stocks to Buy Now Screener and Hot Stocks & Movers Today Screener .
Rotated Stock & Insider Dossiers: Cross-reference institutional dossiers on Hims & Hers Health ($HIMS) ( HIMS WACC ), Strategy Inc. ($MSTR) ( MSTR Piotroski F-Score ), and ASML Holding ($ASML) , alongside verified insider trading disclosures for Jason Warnick (CFO, Robinhood Markets, Inc.) and Rep. Mark E. Green plus macro regime telemetry on 10Y-2Y Treasury Yield Curve Spread (T10Y2Y) .
- Hims & Hers Health ($HIMS) [WACC] [Financials] [10-K RED]
- Strategy Inc. ($MSTR) [Piotroski F-Score] [Dividends] [10-K DES]
- ASML Holding ($ASML) [Peter Lynch Value] [Insiders] [10-K RED]
- Intel Corp. ($INTC) [PEG Ratio] [Financials] [10-K DES]
- Microsoft Corp. ($MSFT) [WACC] [Dividends] [10-K RED]
- Vistra Corp. ($VST) [Piotroski F-Score] [Insiders] [10-K DES]
- Palo Alto Networks ($PANW) [Peter Lynch Value] [Financials] [10-K RED]
- Eli Lilly & Co. ($LLY) [PEG Ratio] [Dividends] [10-K DES]
- Morgan Stanley ($MS) [WACC] [Insiders] [10-K RED]
- Caterpillar Inc. ($CAT) [Piotroski F-Score] [Financials] [10-K DES]
- Netflix Inc. ($NFLX) [Peter Lynch Value] [Dividends] [10-K RED]
- Rocket Lab USA ($RKLB) [PEG Ratio] [Insiders] [10-K DES]
- ZIM Integrated Shipping ($ZIM) [WACC] [Financials] [10-K RED]
- Core Scientific ($CORZ) [Piotroski F-Score] [Dividends] [10-K DES]
- 📐 All 12 Institutional Valuation & Forensic Formulas (/term)
- 🔥 Best Stocks to Buy Now Screener (Top RQD Composite Score (A/A+) + Positive Momentum + Institutional / Insider Accumulation)
- ⚡ Hot Stocks & Movers Today Screener (Largest Daily % Price Swing + High Beta (> 1.25x) + Active Options & Momentum Signal)
- 🎯 Penny Stocks to Watch Screener (Low Share Price (≤ $8.00) + High Beta Volatility + Solvency Floor Filter)
- 💵 Stocks Under $5 Screener (Share Price ≤ $5.50 (or Lowest-Priced Decile) + High Beta + RQD Momentum Rank)
- 🔟 Stocks Under $10 Screener (Share Price ≤ $12.00 (or Lowest-Priced Tier) + Positive Revenue/Cash Trajectory + High RQD Score)
- 🏛️ Congress Stock Tracker Screener (Verified Congressional (House/Senate) Buy or C-Suite Form 4 Accumulation + Live RQD Grade)
- 🏰 Buffett-Munger Moat Screener (ROIC > 15%)
- 📈 Peter Lynch GARP Screener (Spot Price ≤ Peter Lynch Fair Value Line)
- 🛡️ Ben Graham Value Screener (Positive DCF Margin of Safety)
- 🔬 Piotroski F-Score 8–9 Screener (Piotroski F-Score ≥ 7/9)
- 👔 CEO & Congress Buys Screener (Verified Open-Market CEO/CFO Form 4 Buy or Congressional Accumulation + High RQD Cash Engine)
- 💰 High-ROIC Cash Cows Screener (FCF Yield ≥ 4.0%)
- 🚀 Quality Short Squeezes Screener (Elevated Short Interest / Beta + Piotroski F-Score ≥ 6/9 + Safe Altman Z-Score (> 2.2))
- 🚨 Forensic Red Flags Screener (Elevated Dilution (> +2.5% YoY) OR WACC > ROIC OR Extended Valuation Above DCF Band)
- ⚔️ SOFI vs. HOOD Revenue Velocity
- ⚔️ CRWD vs. PANW Cybersecurity Growth
- ⚔️ CAT vs. DE Industrial Capital Efficiency
- ⚔️ IREN vs. CORZ AI Grid Substation Margins
- ⚔️ VRT vs. ETN Liquid Cooling & Grid ROIC
- ⚔️ AAPL vs. MSFT Return on Capital (ROIC)
- 🏛️ Jason Warnick (CFO, Robinhood Markets, Inc.) — $HOOD Trades
- 🏛️ Rep. Mark E. Green (U.S. House (R-TN-07)) — $PLTR Trades
- 🏛️ Sen. Tommy Tuberville (U.S. Senate (R-AL)) — $XOM Trades
- 🏛️ Rep. Michael McCaul (Spouse) (U.S. House (R-TX-10)) — $LMT Trades
- 🏛️ Rep. Marjorie Taylor Greene (U.S. House (R-GA-14)) — $CRWD Trades
- 🏛️ Rep. French Hill (U.S. House (R-AR-02)) — $COIN Trades
- 🏛️ Rep. Suzan DelBene (Spouse) (U.S. House (D-WA-01)) — $AMZN Trades
- 🏛️ Rep. Jared Moskowitz (U.S. House (D-FL-23)) — $META Trades
- 🐋 Citadel Advisors (Ken Griffin) — Multi-Strategy 13F Flow
- 🐋 Duquesne Family Office (Druckenmiller) — Macro & AI Infrastructure 13F
- 🐋 Pershing Square (Bill Ackman) — High-Conviction Compounders 13F
- 🐋 Viking Global Investors — TMT & Industrial Growth 13F
- 🐋 D.E. Shaw & Co. — Quantitative Arbitrage 13F
- 🐋 Lori A. Beer (JPMorgan / Insider) — Verified Form 4 Track Record
- 📰 Urban Edge: Northeast Grocery-Anchored Centers Give This REIT a Dividend Hike Runway ($UE)
- 📰 Wall Street Is Pricing Grid Monopolies Like Disposable Mining Rigs—While the Real Toll Collectors Clean Up ($COIN)
- 📰 Congress vs. Wall Street: Our Audit of 827 Capitol Hill Stock Disclosures Shows Lawmakers Quietly Exiting Consumer Tech for 3 Defense & Grid Bottlenecks ($PLTR)
- 📰 Why High-Multiple Cloud Software Is Getting Punished: Inside Datadog’s Post-Earnings Drop & GAAP Dilution Math ($DDOG)
- 📰 Wall Street Prices Tesla Like a Busted Buick Dealer While Megapack Quietly Prints Cash ($TSLA)
- 📰 ZIM's Variable Dividend Math: Spot Freight Rates Versus a Net Cash Floor Under the Stock ($ZIM)
- 📊 10Y-2Y Treasury Yield Curve Spread (T10Y2Y)
- 📊 10-Year TIPS Real Interest Rate (DFII10)
- 📊 M2 Money Supply Liquidity Stock (M2SL)
- 📊 US Treasury General Account (TGA) (WTREGEN)
- 📊 Personal Consumption Expenditures (PCE) (PCEPI)
- 💡 Defense & Space DoD Obligations Backlog Thesis
- 💡 Starter Kit: AI Power, Liquid Cooling & Substation Grid
- 💡 AI Power Bottleneck & Hyperscaler CapEx Thesis
- 💡 Share-Count Creep, SBC Dilution & 2027 Refinancing Watch
- 💡 Weekly Evidence Audit: Confirmed vs. Overpriced Options
- 🦋 2nd-Order Supply-Chain & Grid Butterfly Map (/butterfly)
- 🔬 30-Second Portfolio Crash & Overlap X-Ray (/xray)
- 🎯 Real-Time Macro Event Probability Engine (/predictions)
- 🏆 $100K Risk-Free Paper Trading Simulation Arena (/arena)